|
Onyx Pharmaceuticals Announces Conference Call to Report Financial Results Of Fourth Quarter and Fiscal Year 2000 RICHMOND, Calif., Feb. 22 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX - news) today announced that it will host a conference call on Wednesday, February 28, 2001, at 4:30 p.m. EST, to discuss the financial results of the fourth quarter and fiscal year 2000. Hollings C. Renton, Chairman and Chief Executive Officer will host the call. To access the conference call, dial 800-498-2168 (within the United States), or 706-634-6592 (if calling from outside the U.S.). An audio replay will be available two hours after the completion of the call through March 14 and can be accessed by dialing 800-642-1687, identification number 280100. A webcast will also be available at www.presentonline.com; click on conference archives and enter identification number x96857. Onyx Pharmaceuticals is engaged in the discovery and development of novel targeted, highly selective cancer therapies. Based on its proprietary virus technologies, the company is developing its lead product, CI-1042 (ONYX-015), a tumor-selective, modified adenovirus (similar to the common cold virus) that has been genetically engineered to replicate in and kill cancer cells that have abnormal p53 pathway function while sparing normal cells. CI-1042 is currently being evaluated in a Phase III clinical trial for head and neck cancer, and is in Phase I and II clinical trials for a number of additional cancer indications. CI-1042 is being jointly developed by Onyx with Warner-Lambert, a subsidiary of Pfizer Inc. This press release contains certain forward-looking statements regarding the development of potential human therapeutic products that involve a number of risks and uncertainties. Actual events may differ from the company`s expectations. In addition to the matters described in this press release, the timeline for clinical activity, results of pending or future clinical trials, and changes in the status of the company`s collaborative relationships, as well as the risk factors listed from time to time in the company`s periodic reports filed with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K, may affect the actual results achieved by the company. SOURCE: Onyx Pharmaceuticals, Inc. |
|
| aus der Diskussion: | onyx pharmaceut. im juhu musterdepot! |
| Autor (Datum des Eintrages): | panik (22.02.01 22:51:40) |
| Beitrag: | 14 von 229 (ID:2965136) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |